In the reprogramming group, expression levels of cancer stem cell markers CD44 and CD133 significantly decreased, from 92.92% to 26.81% and from 88.51% to 16.22%, respectively; moreover, counts of CD44+ and CD133+ cells decreased from 70.20% to 12.20% (Figure 4F, G). The gene discussed is PROM1; the disease is cancer.